All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Post-Hoc Analysis Provides Quantitative Evidence on Efficacy of Frontline mCRPC Treatments After Progression on Apalutamide

March 8th 2023

Boris A. Hadaschik, MD, discusses results from a post-hoc analysis of subsequent therapy for patients with nonmetastatic castration-resistant prostate cancer who progressed following treatment with apalutamide.

Ruxolitinib Demonstrates 6-Month Hematocrit Reduction in Polycythemia Vera

March 8th 2023

Treatment with ruxolitinib significantly reduced hematocrit levels and the number of yearly phlebotomies in patients with polycythemia vera, according to findings from a prespecified futility analysis of the phase 2b RuxoBEAT trial.

Making Pancreatic Cancer Treatments More Effective

March 8th 2023

Pancreatic cancer diagnoses are increasing more rapidly than any other cancer type while remaining one of the most deadly cancers.

FDA Accepts BLA Resubmission for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

March 8th 2023

The FDA’s Office of Therapeutic Products has accepted a resubmission of the biologics license application (BLA) for remestemcel-L for the treatment of pediatric patients with steroid-refractory, acute graft-vs-host-disease.

BET Inhibitors in Cancer Therapy: Finding the Right Combination

March 8th 2023

An understanding of BET protein dysregulation, which leads to abnormal expression of oncogenes, has prompted investigators to explore the idea of these proteins as a therapeutic target for cancer.

Updated MAGNITUDE Data Support Niraparib Combination in mCRPC and HRR Gene Alterations

March 8th 2023

Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.

Palbociclib Plus Aromatase Inhibitor Therapy Provides Real-World Benefit in Older Patients With HR+/HER2– Metastatic Breast Cancer

March 7th 2023

Palbociclib plus an aromatase inhibitor improved real-world data for progression-free survival, overall survival, and time to chemotherapy compared with an aromatase inhibitor alone in patients 75 years and older with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.

ADCs Advance HR+/HER2– Breast Cancer Treatment Paradigm

March 7th 2023

As more antibody-drug conjugates emerge and investigators foresee fam-trastuzumab deruxtecan-nxki moving forward in lines of treatment for metastatic disease, the treatment landscape of hormone receptor–positive, HER2-negative breast cancer continues to expand and shift.

Updated CheckMate 274 Data Reaffirm Benefit of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

March 7th 2023

Matthew Galsky, MD, discusses the key long-term findings and the clinical implications of the updated data from the phase 3 CheckMate 274 trial of nivolumab for the adjuvant treatment of patients with urothelial carcinoma.

New Generation of TKIs Challenge Standards of Care in Newly Diagnosed Ph+ ALL

March 7th 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.

FDA Expands Approval for Companion Diagnostic for Cemiplimab in NSCLC

March 7th 2023

The FDA has approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

EU Approves Luspatercept for Anemia in Patients with Non–Transfusion-Dependent Beta Thalassemia

March 7th 2023

The European Commission has granted a full marketing authorization to luspatercept-aamt for use in adult patients with anemia associated with non–transfusion-dependent β-thalassemia.

Cabozantinib Plus Atezolizumab Misses PFS End Point in Previously Treated Advanced RCC

March 7th 2023

The combination of cabozantinib and atezolizumab did not significantly improve progression-free survival over cabozantinib alone in patients with locally advanced or metastatic clear cell or non–clear cell renal cell carcinoma who progressed during or following checkpoint inhibition, missing the primary end point of the phase 3 CONTACT-03 trial.

Lasofoxifene May Improve Vaginal/Vulvar Symptoms in Postmenopausal ER+/HER2–, ESR1-Mutated Breast Cancer

March 6th 2023

Lasofoxifene improved vaginal/vulvar symptoms compared with fulvestrant in premenopausal patients with locally advanced or metastatic estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

CEACAM5-Directed Tusamitamab Ravtansine Progresses to Phase 3 Trial in NSCLC

March 6th 2023

Clinicians tasked with treating patients with non–small cell lung cancer may soon be gaining an additional therapeutic target, this one directed at CEACAM5.

Incyte to Discontinue Phase 3 LIMBER-304 Trial of Parsaclisib Plus Ruxolitinib in Myelofibrosis

March 6th 2023

The phase 3 LIMBER-304 trial evaluating parsaclisib plus ruxolitinib in patients with myelofibrosis will be discontinued after results of a preplanned interim analysis indicated that the study is unlikely to meet its primary end point of targeted reduction in spleen volume in the intent-to-treat population.

Florida Cancer Specialists & Research Institute Names Sachin Kamath, MD Compliance Committee Chairman

March 6th 2023

Florida Cancer Specialists & Research Institute has appointed Sachin Kamath, MD as Chairman of the FCS Executive Board Compliance Committee.

FDA Approves Biosimilar Pegfilgrastim-cbqv for Febrile Neutropenia

March 6th 2023

The FDA has approved a single-dose, prefilled autoinjector presentation of pegfilgrastim-cbqv (Udenyca), which is a biosimilar of pegfilgrastim that is given the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Trastuzumab Deruxtecan Meets ORR End Point in HER2-expressing Advanced Solid Tumors

March 6th 2023

The antibody-drug conjugate trastuzumab deruxtecan met the prespecified target for objective response rate and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial.

MDS Options Are Poised to Expand Across Risk Groups

March 6th 2023

Findings from several large phase 3 studies along with continued development of emerging therapies promise to alter the treatment landscape for patients with myelodysplastic syndromes.